Future therapy of portal hypertension in liver cirrhosis - A guess

F1000Prime Reports

Volumn 6, Issue , 2014, Pages

  Sauerbruch, Tilman ^a   Trebicka, Jonel ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE;

ADRENERGIC SYSTEM; ALCOHOLIC FATTY LIVER; ARTICLE; DISEASE ASSOCIATION; FUTUROLOGY; HUMAN; HYPOTHESIS; INFECTION; INTESTINE; INTESTINE FUNCTION; INTRACELLULAR SIGNALING; INTRAHEPATIC RESISTANCE; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PERSONALIZED MEDICINE; PHYSICAL RESISTANCE; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; REMISSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHUNTING; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; VIRUS INFECTION; VIRUS PATHOGENESIS;

EID: 84908238560     PISSN: 20517599     EISSN: 20517599     Source Type: Journal    
DOI: 10.12703/P6-95     Document Type: Article

References (183)

1. Vorobioff JD: Hepatic venous pressure in practice: how, when, and why. J Clin Gastroenterol 2007, 41(Suppl 3):S336-43.
2. Wong F, Liu P, Tobe S, Morali G, Blendis L: Central blood volume in cirrhosis: measurement with radionuclide angiography. Hepatology 1994, 19:312-21.
3. Blendis L, Wong F: The hyperdynamic circulation in cirrhosis: an overview. Pharmacol Ther 2001, 89:221-31.
4. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker- Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, et al.: Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2095-128.
5. European Association For The Study Of The Liver: EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012, 57:167-85.
6. European Association For The Study Of The Liver: EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014, 60:392-420.
7. Chung RT, Baumert TF: Curing chronic hepatitis C-the arc of a medical triumph. N Engl J Med 2014, 370:1576-8.
8. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P; ION-1 Investigators: Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014, 370:1889-98.
9. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P; ION-2 Investigators: Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014, 370:1483-93.
10. Hoofnagle JH, Sherker AH: Therapy for hepatitis C-the costs of success. N Engl J Med 2014, 370:1552-3.
11. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Schall RA, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ: Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year openlabel follow-up study. Lancet 2013, 381:468-75.
12. Arthur MJ: Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology 2002, 122:1525-8.
13. Kweon YO, Goodman ZD, Dienstag JL, Schiff ER, Brown NA, Burchardt E, Schoonhoven R, Brenner DA, Fried MW: Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol 2001, 35:749-55.
14. Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G, Örmeci N, Van Vlierberghe H, Gschwantler M, Akarca U, Aleman S, Balik I, Berg T, Bihl F, Bilodeau M, Blasco AJ, Brandão Mello CE, Bruggmann P, Calinas F, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cornberg M, Cramp ME, Dore GJ, Doss W, El-Sayed MH, Ergör G, et al.: Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat 2014, 21(Suppl 1):60-89.
15. European Association For The Study Of The Liver: EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 2012, 57:399-420.
16. Zatonski WA, Sulkowska U, Manczuk M, Rehm J, Boffetta P, Lowenfels AB, La Vecchia C: Liver cirrhosis mortality in Europe, with special attention to Central and Eastern Europe. Eur Addict Res 2010, 16:193-201.
17. Holm AL, Veerman L, Cobiac L, Ekholm O, Diderichsen F: Cost-effectiveness of preventive interventions to reduce alcohol consumption in Denmark. PLoS One 2014, 9:e88041.
18. Holm AL, Veerman L, Cobiac L, Ekholm O, Diderichsen F: Cost-effectiveness of changes in alcohol taxation in Denmark: a modelling study. Cost Eff Resour Alloc 2014, 12:1.
19. Schnabl B, Brenner DA: Interactions between the intestinal microbiome and liver diseases. Gastroenterology 2014, 146:1513-24.
20. Liedtke C, Luedde T, Sauerbruch T, Scholten D, Scholten D, Streetz K, Tacke F, Tolba R, Trautwein C, Trebicka J, Weiskirchen R: Experimental liver fibrosis research: update on animal models, legal issues and translational aspects. Fibrogenesis Tissue Repair 2013, 6:19.
21. Mathews S, Xu M, Wang H, Bertola A, Gao B: Animals Models of Gastrointestinal and Liver Diseases. Animal models of alcohol-induced liver disease: pathophysiology, translational relevance, and challenges. Am J Physiol Gastrointest Liver Physiol 2014, 306:G819-23.
22. Nadalin S, Malago M, Valentin-Gamazo C, Testa G, Baba HA, Liu C, Frühauf NR, Schaffer R, Gerken G, Frilling A, Broelsch CE: Preoperative donor liver biopsy for adult living donor liver transplantation: risks and benefits. Liver Transpl 2005, 11:980-6.
23. Minervini MI, Ruppert K, Fontes P, Volpes R, Volpes R, Vizzini G, de Vera ME, Gruttadauria S, Miraglia R, Pipitone L, Marsh JW, Marcos A, Gridelli B, Demetris AJ: Liver biopsy findings from healthy potential living liver donors: reasons for disqualification, silent diseases and correlation with liver injury tests. J Hepatol 2009, 50:501-10.
24. Anstee QM, Targher G, Day CP: Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013, 10:330-44.
25. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P: The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129:113-21.
26. Mendes FD, Suzuki A, Sanderson SO, Lindor KD, Angulo P: Prevalence and indicators of portal hypertension in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2012, 10:1028-33. e1022.
27. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S: Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44:865-73.
28. Argo CK, Caldwell SH: Epidemiology and natural history of nonalcoholic steatohepatitis. Clin Liver Dis 2009, 13:511-31.
29. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH: Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009, 51:371-9.
30. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G: A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010, 53:372-84.
31. Angulo P: GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2007, 25:883-9.
32. Dongiovanni P, Donati B, Fares R, Lombardi R, Mancina RM, Romeo S, Valenti L: PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol 2013, 19:6969-78.
33. Anstee QM, McPherson S, Day CP: How big a problem is nonalcoholic fatty liver disease? BMJ 2011, 343:d3897.
34. Lassailly G, Caiazzo R, Hollebecque A, Buob D, Leteurtre E, Arnalsteen L, Louvet A, Pigeyre M, Raverdy V, Verkindt H, Six MF, Eberle C, Patrice A, Dharancy S, Romon M, Pattou F, Mathurin P: Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity. Eur J Gastroenterol Hepatol 2011, 23:499-506.
35. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, Fava JL, Wing RR: Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010, 51:121-9.
36. Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M: Bariatric surgery for nonalcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 2010, 1:CD007340.
37. Mosko JD, Nguyen GC: Increased perioperative mortality following bariatric surgery among patients with cirrhosis. Clin Gastroenterol Hepatol 2011, 9:897-901.
38. Ostlund MP, Backman O, Marsk R, Stockeld D, Lagergren J, Rasmussen F, Naslund E: Increased admission for alcohol dependence after gastric bypass surgery compared with restrictive bariatric surgery. JAMA Surg 2013, 148:374-7.
39. Felipo V, Urios A, Garcia-Torres ML, El Mlili N, del Olmo JA, del Olmo JA, Civera M, Ortega J, Ferrandez A, Martínez-Valls J, Cassinello N, Montoliu C: Alterations in adipocytokines and cGMP homeostasis in morbid obesity patients reverse after bariatric surgery. Obesity (Silver Spring) 2013, 21:229-37.
40. Lassailly G, Caiazzo R, Pattou F, Mathurin P: Bariatric surgery for curing NASH in the morbidly obese? J Hepatol 2013, 58:1249-51.
41. Trebicka J, Hennenberg M, Laleman W, Shelest N, Shelest N, Biecker E, Schepke M, Nevens F, Sauerbruch T, Heller J: Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 2007, 46:242-53.
42. Trebicka J, Hennenberg M, Odenthal M, Shir K, Klein S, Granzow M, Vogt A, Dienes HP, Lammert F, Reichen J, Heller J, Sauerbruch T: Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. J Hepatol 2010, 53:702-12.
43. Klein S, Klosel J, Schierwagen R, Körner C, Granzow M, Huss S, Mazar IG, Weber S, van den Ven PF, Pieper-Fürst U, Fürst DO, Nattermann J, Lammert F, Sauerbruch T, Trebicka J: Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats. Lab Invest 2012, 92:1440-50.
44. Shirai Y, Yoshiji H, Noguchi R, Kaji K, Aihara Y, Douhara A, Moriya K, Namisaki T, Kawaratani H, Fukui H: Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2013, 28:723-30.
45. Toblli JE, Munoz MC, Cao G, Mella J, Pereyra L, Mastai R: ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. Obesity (Silver Spring) 2008, 16:770-6.
46. Kudo H, Yata Y, Takahara T, Kawai K, Nakayama Y, Kanayama M, Oya T, Morita S, Sasahara M, Mann DA, Sugiyama T: Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue. Liver Int 2009, 29:988-96.
47. Kato J, Koda M, Kishina M, Tokunaga S, Matono T, Sugihara T, Sugihara T, Ueki M, Murawaki Y: Therapeutic effects of angiotensin II type 1 receptor blocker, irbesartan, on nonalcoholic steatohepatitis using FLS-ob/ob male mice. Int J Mol Med 2012, 30:107-13.
48. Friedman SL: Mechanisms of hepatic fibrogenesis. Gastroenterology 2008, 134:1655-69.
49. Schuppan D, Kim YO: Evolving therapies for liver fibrosis. J Clin Invest 2013, 123:1887-901.
50. Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA: Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol 2014, 14:181-94.
51. Patsenker E, Popov Y, Stickel F, Jonczyk A, Goodman SL, Schuppan D: Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology 2008, 135:660-70.
52. Patsenker E, Popov Y, Stickel F, Schneider V, Ledermann M, Sägesser H, Niedobitek G, Goodman SL, Schuppan D: Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology 2009, 50:1501-11.
53. Henderson NC, Arnold TD, Katamura Y, Giacomini MM, Rodriguez JD, McCarty JH, Pellicoro A, Raschperger E, Betsholtz C, Ruminski PG, Griggs DW, Prinsen MJ, Maher JJ, Iredale JP, Lacy- Hulbert A, Adams RH, Sheppard D: Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med 2013, 19:1617-24.
54. Pinzani M, Milani S, De Franco R, Grappone C, Caligiuri A, Gentilini A, Tosti-Guerra C, Maggi M, Failli P, Ruocco C, Gentilini P: Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology 1996, 110:534-48.
55. Svegliati-Baroni G, Ridolfi F, Caradonna Z, Alvaro D, Marzioni M, Saccomanno S, Candelaresi C, Trozzi L, Macarri G, Benedetti A, Folli F: Regulation of ERK/JNK/p70S6K in two rat models of liver injury and fibrosis. J Hepatol 2003, 39:528-37.
56. Sancho-Bru P, Bataller R, Colmenero J, Gasull X, Moreno M, Arroyo V, Brenner DA, Ginès P: Norepinephrine induces calcium spikes and proinflammatory actions in human hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2006, 291:G877-84.
57. Verbeke L, Farre R, Trebicka J, Komuta M, Roskams T, Klein S, Elst IV, Windmolders P, Vanuytsel T, Nevens F, Laleman W: Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 2014, 59:2286-98.
58. Granzow M, Schierwagen R, Klein S, Kowallick B, Huss S, Linhart M, Mazar IG, Görtzen J, Vogt A, Schildberg FA, Gonzalez-Carmona MA, Wojtalla A, Krämer B, Nattermann J, Siegmund SV, Werner N, Fürst DO, Laleman W, Knolle P, Shah VH, Sauerbruch T, Trebicka J: Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis. Hepatology 2014, 60:334-48.
59. Li T, Eheim AL, Klein S, Uschner FE, Smith AC, Smith AC, Brandon-Warner E, Ghosh S, Bonkovsky HL, Trebicka J, Schrum LW: Novel role of nuclear receptor Rev-erbalpha in hepatic stellate cell activation: potential therapeutic target for liver injury. Hepatology 2014, 59:2383-96.
60. Ehling J, Bartneck M, Wei X, Gremse F, Fech V, Möckel D, Baeck C, Hittatiya K, Eulberg D, Luedde T, Kiessling F, Trautwein C, Lammers T, Tacke F: CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis. Gut 2014, [Epub ahead of print].
61. Tacke F, Zimmermann HW: Macrophage heterogeneity in liver injury and fibrosis. J Hepatol 2014, 60:1090-6.
62. Heller J, Shiozawa T, Trebicka J, Hennenberg M, Schepke M, Neef M, Sauerbruch T: Acute haemodynamic effects of losartan in anaesthetized cirrhotic rats. Eur J Clin Invest 2003, 33:1006-1012.
63. Heller J, Trebicka J, Shiozawa T, Schepke M, Neef M, Hennenberg M, Sauerbruch T: Vascular, hemodynamic and renal effects of lowdose losartan in rats with secondary biliary cirrhosis. Liver Int 2005, 25:657-66.
64. Zhou Q, Hennenberg M, Trebicka J, Jochem K, Jochem K, Leifeld L, Biecker E, Sauerbruch T, Heller J: Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis. Gut 2006, 55:1296-305.
65. Hennenberg M, Biecker E, Trebicka J, Jochem K, Zhou Q, Schmidt M, Jakobs KH, Sauerbruch T, Heller J: Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats. Gastroenterology 2006, 130:838-54.
66. Moreno M, Gonzalo T, Kok RJ, Sancho-Bru P, van Beuge M, Swart J, Prakash J, Temming K, Fondevila C, Beljaars L, Lacombe M, van der Hoeven P, Arroyo V, Poelstra K, Brenner DA, Ginès P, Bataller R: Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. Hepatology 2010, 51:942-52.
67. van Beuge MM, Prakash J, Lacombe M, Gosens R, Post E, Reker- Smit C, Beljaars L, Poelstra K: Reduction of fibrogenesis by selective delivery of a Rho kinase inhibitor to hepatic stellate cells in mice. J Pharmacol Exp Ther 2011, 337:628-35.
68. van Beuge MM, Prakash J, Lacombe M, Post E, Reker-Smit C, Beljaars L, Poelstra K: Increased Liver Uptake and Reduced Hepatic Stellate Cell Activation with a Cell-Specific Conjugate of the Rho-kinase Inhibitor Y27632. Pharm Res 2011, 28:2045-54.
69. Klein S, Van Beuge MM, Granzow M, Beljaars L, Schierwagen R, Kilic S, Heidari I, Huss S, Sauerbruch T, Poelstra K, Trebicka J: HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects. J Hepatol 2012, 57:1220-7.
70. Bansal R, Prakash J, Post E, Beljaars L, Schuppan D, Poelstra K: Novel engineered targeted interferon-gamma blocks hepatic fibrogenesis in mice. Hepatology 2011, 54:586-96.
71. Melgert BN, Olinga P, Van Der Laan JM, Weert B, Cho J, Schuppan D, Groothuis GM, Meijer DK, Poelstra K: Targeting dexamethasone to Kupffer cells: effects on liver inflammation and fibrosis in rats. Hepatology 2001, 34:719-28.
72. Bartneck M, Peters FM, Warzecha KT, Bienert M, van Bloois L, Trautwein C, Lammers T, Tacke F: Liposomal encapsulation of dexamethasone modulates cytotoxicity, inflammatory cytokine response, and migratory properties of primary human macrophages. Nanomedicine 2014, 10:1209-20.
73. Steib CJ, Hennenberg M, Beitinger F, Hartmann AC, Bystron M, De Toni EN, Gerbes AL: Amiloride reduces portal hypertension in rat liver cirrhosis. Gut 2010, 59:827-36.
74. Steib CJ, Bilzer M, op den Winkel M, Pfeiler S, Hartmann AC, Hennenberg M, Göke B, Gerbes AL: Treatment with the leukotriene inhibitor montelukast for 10 days attenuates portal hypertension in rat liver cirrhosis. Hepatology 2010, 51:2086-96.
75. Lin HC, Yang YY, Tsai TH, Huang CM, Huang YT, Lee FY, Liu TT, Lee SD: The relationship between endotoxemia and hepatic endocannabinoids in cirrhotic rats with portal hypertension. J Hepatol 2011, 54:1145-53.
76. Steib CJ: Kupffer cell activation and portal hypertension. Gut 2011, 60:1307-08.
77. Holland-Fischer P, Gronbaek H, Sandahl TD, Moestrup SK, Riggio O, Ridola L, Aagaard NK, Møller HJ, Vilstrup H: Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS. Gut 2011, 60:1389-93.
78. Trebicka J, Krag A, Gansweid S, Appenrodt B, Schiedermaier P, Sauerbruch T, Spengler U: Endotoxin and tumor necrosis factorreceptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt. Eur J Gastroenterol Hepatol 2011, 23:1218-25.
79. Trebicka J, Krag A, Gansweid S, Schiedermaier P, Strunk HM, Fimmers R, Strassburg CP, Bendtsen F, Møller S, Sauerbruch T, Spengler U: Soluble TNF-alpha-receptors I are prognostic markers in TIPS-treated patients with cirrhosis and portal hypertension. PLoS One 2013, 8:e83341.
80. Wiest R, Groszmann RJ: Nitric oxide and portal hypertension: its role in the regulation of intrahepatic and splanchnic vascular resistance. Semin Liver Dis 1999, 19:411-26.
81. Fiorucci S, Antonelli E, Morelli O, Mencarelli A, Casini A, Mello T, Palazzetti B, Tallet D, del Soldato P, Morelli A: NCX-1000, a NOreleasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension. Proc Natl Acad Sci USA 2001, 98:8897-902.
82. Fiorucci S, Antonelli E, Tocchetti P, Morelli A: Treatment of portal hypertension with NCX-1000, a liver-specific NO donor. A review of its current status. Cardiovasc Drug Rev 2004, 22:135-46.
83. Biecker E, Trebicka J, Kang A, Hennenberg M, Sauerbruch T, Heller J: Treatment of bile duct-ligated rats with the nitric oxide synthase transcription enhancer AVE 9488 ameliorates portal hypertension. Liver Int 2008, 28:331-8.
84. Zafra C, Abraldes JG, Turnes J, Berzigotti A, Fernandez M, Garca-Pagán JC, Rodés J, Bosch J: Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 2004, 126:749-55.
85. Abraldes JG, Rodriguez-Vilarrupla A, Graupera M, Zafra C, Garcia-Caldero H, Garcia-Pagan JC, Bosch J: Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. J Hepatol 2007, 46:1040-6.
86. Abraldes JG, Albillos A, Banares R, Turnes J, Gonzalez R, Garcia-Pagan JC, Bosch J: Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 2009, 136:1651-8.
87. Woitas RP, Heller J, Stoffel-Wagner B, Spengler U, Sauerbruch T: Renal functional reserve and nitric oxide in patients with compensated liver cirrhosis. Hepatology 1997, 26:858-64.
88. Woitas RP, Flommersfeld S, Stoffel-Wagner B, Schiedermaier P, Brensing KA, Spengler U, Sauerbruch T: Renal functional reserve is well maintained in patients with advanced liver cirrhosis and ascites. Scand J Gastroenterol 2002, 37:1321-7.
89. Kobori H, Nangaku M, Navar LG, Nishiyama A: The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007, 59:251-87.
90. Bataller R, Sancho-Bru P, Gines P, Brenner DA: Liver fibrogenesis: a new role for the renin-angiotensin system. Antioxid Redox Signal 2005, 7:1346-55.
91. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J: Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988, 8:1151-7.
92. Oakley F, Teoh V, Ching ASG, Bataller R, Colmenero J, Jonsson JR, Eliopoulos AG, Watson MR, Manas D, Mann DA: Angiotensin II activates I kappaB kinase phosphorylation of RelA at Ser 536 to promote myofibroblast survival and liver fibrosis. Gastroenterology 2009, 136:2334-44. e2331.
93. Bataller R, Gines P, Nicolas JM, Gorbig MN, Garcia-Ramallo E, Gasull X, Bosch J, Arroyo V, Rodés J: Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000, 118:1149-56.
94. Bataller R, Gabele E, Parsons CJ, Morris T, Yang L, Schoonhoven R, Brenner DA, Rippe RA: Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. Hepatology 2005, 41:1046-55.
95. Yang L, Bataller R, Dulyx J, Coffman TM, Gines P, Rippe RA, Brenner DA: Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice. J Hepatol 2005, 43:317-23.
96. Wei Y, Clark SE, Morris EM, Thyfault JP, Uptergrove GM, Whaley-Connell AT, Ferrario CM, Sowers JR, Ibdah JA: Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats. J Hepatol 2008, 49:417-28.
97. Grace JA, Herath CB, Mak KY, Burrell LM, Angus PW: Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options. Clin Sci (Lond) 2012, 123:225-39.
98. Tandon P, Abraldes JG, Berzigotti A, Garcia-Pagan JC, Bosch J: Renin-angiotensin- aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis. J Hepatol 2010, 53:273-82.
99. Schneider AW, Kalk JF, Klein CP: Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 1999, 29:334-9.
100. Schepke M, Werner E, Biecker E, Schiedermaier P, Heller J, Neef M, Stoffel-Wagner B, Hofer U, Caselmann WH, Sauerbruch T: Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology 2001, 121:389-95.
101. Girgrah N, Liu P, Collier J, Blendis L, Wong F: Haemodynamic, renal sodium handling, and neurohormonal effects of acute administration of low dose losartan, an angiotensin II receptor antagonist, in preascitic cirrhosis. Gut 2000, 46:114-20.
102. Wong F, Liu P, Blendis L: The mechanism of improved sodium homeostasis of low-dose losartan in preascitic cirrhosis. Hepatology 2002, 35:1449-58.
103. Schepke M, Wiest R, Flacke S, Heller J, Stoffel-Wagner B, Herold T, Ghauri M, Sauerbruch T: Irbesartan plus low-dose propranolol versus low-dose propranolol alone in cirrhosis: a placebocontrolled, double-blind study. Am J Gastroenterol 2008, 103:1152-8.
104. Grace JA, Klein S, Herath CB, Granzow M, Schierwagen R, Masing N, Walther T, Sauerbruch T, Burrell LM, Angus PW, Trebicka J: Activation of the MAS receptor by angiotensin-(1-7) in the renin-angiotensin system mediates mesenteric vasodilatation in cirrhosis. Gastroenterology 2013, 145:874-84. e875.
105. Antunes LC, Davies JE, Finlay BB: Chemical signaling in the gastrointestinal tract. F1000 Biol Rep 2011, 3:4.
106. Henao-Mejia J, Elinav E, Strowig T, Flavell RA: Inflammasomes: far beyond inflammation. Nat Immunol 2012, 13:321-4.
107. Strowig T, Henao-Mejia J, Elinav E, Flavell R: Inflammasomes in health and disease. Nature 2012, 481:278-86.
108. Szabo G, Csak T: Inflammasomes in liver diseases. J Hepatol 2012, 57:642-54.
109. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, Thaiss CA, Kau AL, Eisenbarth SC, Jurczak MJ, Camporez JP, Shulman GI, Gordon JI, Hoffman HM, Flavell RA: Inflammasomemediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012, 482:179-85.
110. Lepage P, Leclerc MC, Joossens M, Mondot S, Blottière HM, Raes J, Ehrlich D, Doré J: A metagenomic insight into our gut's microbiome. Gut 2013, 62:146-58.
111. Vlachogiannakos J, Saveriadis AS, Viazis N, Theodoropoulos I, Foudoulis K, Manolakopoulos S, Raptis S, Karamanolis DG: Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Aliment Pharmacol Ther 2009, 29:992-99.
112. Kalambokis GN, Mouzaki A, Rodi M, Pappas K, Fotopoulos A, Xourgia X, Tsianos EV: Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites. Clin Gastroenterol Hepatol 2012, 10:815-8.
113. Vlachogiannakos J, Viazis N, Vasianopoulou P, Vafiadis I, Karamanolis DG, Ladas SD: Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol 2013, 28:450-5.
114. Papatheodoridis GV, Goulis J, Leandro G, Patch D, Burroughs AK: Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: A meta-analysis. Hepatology 1999, 30:612-22.
115. Burroughs AK, Vangeli M: Transjugular intrahepatic portosystemic shunt versus endoscopic therapy: randomized trials for secondary prophylaxis of variceal bleeding: an updated metaanalysis. Scand J Gastroenterol 2002, 37:249-52.
116. Inagaki T, Moschetta A, Lee YK, Peng L, Zhao G, Downes M, Yu RT, Shelton JM, Richardson JA, Repa JJ, Mangelsdorf DJ, Kliewer SA: Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci USA 2006, 103:3920-5.
117. Stojancevic M, Stankov K, Mikov M: The impact of farnesoid X receptor activation on intestinal permeability in inflammatory bowel disease. Can J Gastroenterol 2012, 26:631-7.
118. Verbeke L, Farre R, Covens K, Verbinnen BV, T., Elst IV, Windmolders PV, J., Komuta M, Roskams T, Trebicka J, Nevens F, Laleman W: Obeticholic acid, a Farnesoid-X Receptor-agonist, reduces bacterial translocation and restores intestinal permeability in a rat model of cholestatic liver disease. J Hepatol 2014, 60:S1-22.
119. D' Amico G, Pagliaro L, Bosch J: The treatment of portal hypertension: ameta-analytic review. Hepatology 1995, 22:332-54.
120. Conn HO, Lindenmuth WW: Prophylactic Portacaval Anastomosis in Cirrhotic Patients with Esophageal Varices: A Progress Report of a Continuing Study. N Engl J Med 1965, 272:1255-63.
121. Ring EJ, Lake JR, Roberts JP, Gordon RL, LaBerge JM, Read AE, Sterneck MR, Ascher NL: Using transjugular intrahepatic portosystemic shunts to control variceal bleeding before liver transplantation. Ann Intern Med 1992, 116:304-9.
122. Rossle M: TIPS: 25 years later. J Hepatol 2013, 59:1081-93.
123. Brensing KA, Textor J, Perz J, Schiedermaier P, Schiedermaier P, Raab P, Strunk H, Klehr HU, Kramer HJ, Spengler U, Schild H, Sauerbruch T: Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000, 47:288-95.
124. Monescillo A, Martinez-Lagares F, Ruiz-del-Arbol L, Sierra A, Guevara C, Jiménez E, Marrero JM, Buceta E, Sánchez J, Castellot A, Peñate M, Cruz A, Peña E: Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology 2004, 40:793-801.
125. Garcia-Pagan JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, Abraldes JG, Nevens F, Vinel JP, Mössner J, Bosch J: Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010, 362:2370-9.
126. Garcia-Pagan JC, Di Pascoli M, Caca K, Laleman W, Bureau C, Appenrodt B, Luca A, Zipprich A, Abraldes JG, Nevens F, Vinel JP, Sauerbruch T, Bosch J: Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol 2013, 58:45-50.
127. Orloff MJ: Fifty-three years' experience with randomized clinical trials of emergency portacaval shunt for bleeding esophageal varices in Cirrhosis: 1958-2011. JAMA Surg 2014, 149:155-69.
128. Goulis J, Patch D, Burroughs AK: Bacterial infection in the pathogenesis of variceal bleeding. Lancet 1999, 353:139-42.
129. Goulis J, Armonis A, Patch D, Sabin C, Greenslade L, Burroughs AK: Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 1998, 27:1207-12.
130. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, Durand F, Gustot T, Saliba F, Domenicali M, Gerbes A, Wendon J, Alessandria C, Laleman W, Zeuzem S, Trebicka J, Bernardi M, Arroyo V; CANONIC Study Investigators of the EASL-CLIF Consortium: Acute-onchronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013, 144:1426-37, 1437e1421-1429.
131. Ioannou GN, Kowdley KV: Review: antibiotic prophylaxis reduces mortality and bacterial infection in cirrhosis and gastrointestinal bleeding. ACP J Club 2002, 137:94.
132. Bernard B, Grange JD, Khac EN, Amiot X, Opolon P, Poynard T: Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999, 29:1655-61.
133. Bruns T, Peter J, Reuken PA, Grabe DH, Schuldes SR, Brenmoehl J, Schölmerich J, Wiest R, Stallmach A: NOD2 gene variants are a risk factor for culture-positive spontaneous bacterial peritonitis and monomicrobial bacterascites in cirrhosis. Liver Int 2012, 32:223-30.
134. Appenrodt B, Grunhage F, Gentemann MG, Thyssen L, Sauerbruch T, Lammert F: Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. Hepatology 2010, 51:1327-33.
135. Jalan R, Fernandez J, Wiest R, Schnabl B, Moreau R, Angeli P, Stadlbauer V, Gustot T, Bernardi M, Canton R, Albillos A, Lammert F, Wilmer A, Mookerjee R, Vila J, Garcia-Martinez R, Wendon J, Such J, Cordoba J, Sanyal A, Garcia-Tsao G, Arroyo V, Burroughs A, Ginès P: Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013. J Hepatol 2014, 60:1310-24.
136. Groszmann RJ: Beta-adrenergic blockers and nitrovasodilators for the treatment of portal hypertension: the good, the bad, the ugly. Gastroenterology 1997, 113:1794-7.
137. Hennenberg M, Trebicka J, Sauerbruch T, Heller J: Mechanisms of extrahepatic vasodilation in portal hypertension. Gut 2008, 57:1300-14.
138. Trebicka J, Hennenberg M, Schulze Pröbsting A, Laleman W, Klein S, Granzow M, Nevens F, Zaagsma J, Heller J, Sauerbruch T: Role of beta3-adrenoceptors for intrahepatic resistance and portal hypertension in liver cirrhosis. Hepatology 2009, 50:1924-35.
139. Lebrec D, Nouel O, Corbic M, Benhamou JP: Propranolol-amedical treatment for portal hypertension? Lancet 1980, 2:180-2.
140. Lebrec D, Hillon P, Munoz C, Goldfarb G, Nouel O, Benhamou JP: The effect of propranolol on portal hypertension in patients with cirrhosis: a hemodynamic study. Hepatology 1982, 2:523-7.
141. Poynard T, Cales P, Pasta L, Ideo G, Pascal JP, Pagliaro L, Lebrec D: Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter Study Group. N Engl J Med 1991, 324:1532-8.
142. Tripathi D, Ferguson JW, Kochar N, Leithead JA, Therapondos G, McAvoy NC, Stanley AJ, Forrest EH, Hislop WS, Mills PR, Hayes PC: Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. Hepatology 2009, 50:825-33.
143. Reiberger T, Ulbrich G, Ferlitsch A, Payer BA, Schwabl P, Pinter M, Heinisch BB, Trauner M, Kramer L, Peck-Radosavljevic M; Vienna Hepatic Hemodynamic Lab: Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut 2013, 62:1634-41.
144. Serste T, Melot C, Francoz C, Durand F, Rautou PE, Valla D, Moreau R, Lebrec D: Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2011, 52:1017-22.
145. Krag A, Wiest R, Albillos A, Gluud LL: The window hypothesis: haemodynamic and non-haemodynamic effects of betablockers improve survival of patients with cirrhosis during a window in the disease. Gut 2012, 61:967-9.
146. Mandorfer M, Bota S, Schwabl P, Bucsics T, Pfisterer N, Kruzik M, Hagmann M, Blacky A, Ferlitsch A, Sieghart W, Trauner M, Peck- Radosavljevic M, Reiberger T: Nonselective beta Blockers Increase Risk for Hepatorenal Syndrome and Death in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis. Gastroenterology 2014, 146:1680-90. e1681.
147. Stickel F, Hampe J: Genetic determinants of alcoholic liver disease. Gut 2012, 61:150-9.
148. Nischalke HD, Berger C, Aldenhoff K, Thyssen L, Gentemann M, Grünhage F, Lammert F, Nattermann J, Sauerbruch T, Spengler U, Appenrodt B: Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis. J Hepatol 2011, 55:1010-6.
149. Nischalke HD, Berger C, Luda C, Müller T, Berg T, Coenen M, Krämer B, Körner C, Trebicka J, Grünhage F, Lammert F, Nattermann J, Sauerbruch T, Spengler U: The CXCL1 rs4074 A allele is associated with enhanced CXCL1 responses to TLR2 ligands and predisposes to cirrhosis in HCV genotype 1-infected Caucasian patients. J Hepatol 2012, 56:758-64.
150. Nischalke HD, Berger C, Luda C, Berg T, Müller T, Grünhage F, Lammert F, Coenen M, Krämer B, Körner C, Vidovic N, Oldenburg J, Nattermann J, Sauerbruch T, Spengler U: The PNPLA3 rs738409 148M/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis. PLoS One 2011, 6:e27087.
151. Teixeira-Clerc F, Julien B, Grenard P, Tran Van Nhieu J, Deveaux V, Li L, Serriere-Lanneau V, Ledent C, Mallat A, Lotersztajn S: CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 2006, 12:671-6.
152. Trebicka J, Racz I, Siegmund SV, Cara E, Granzow M, Schierwagen R, Klein S, Wojtalla A, Hennenberg M, Huss S, Fischer HP, Heller J, Zimmer A, Sauerbruch T: Role of cannabinoid receptors in alcoholic hepatic injury: steatosis and fibrogenesis are increased in CB(2) receptor-deficient mice and decreased in CB(1) receptor knockouts. Liver Int 2011, 31:862-72.
153. Huang HC, Wang SS, Hsin IF, Chang CC, Lee FY, Lin HC, Chuang CL, Lee JY, Hsieh HG, Lee SD: Cannabinoid receptor 2 agonist ameliorates mesenteric angiogenesis and portosystemic collaterals in cirrhotic rats. Hepatology 2012, 56:248-58.
154. Steib CJ, Gmelin L, Pfeiler S, Schewe J, Brand S, Goke B, Gerbes AL: Functional relevance of the cannabinoid receptor 2 - heme oxygenase pathway: a novel target for the attenuation of portal hypertension. Life Sci 2013, 93:543-51.
155. Sahin H, Trautwein C, Wasmuth HE: Functional role of chemokines in liver disease models. Nat Rev Gastroenterol Hepatol 2010, 7:682-90.
156. Fernandez M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J: Angiogenesis in liver disease. J Hepatol 2009, 50:604-20.
157. Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M: Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 2009, 49:1245-56.
158. Hennenberg M, Trebicka J, Kohistani Z, Stark C, Nischalke HD, Krämer B, Körner C, Klein S, Granzow M, Fischer HP, Heller J, Sauerbruch T: Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis. Lab Invest 2010, 91:241-51.
159. D'Amico M, Mejias M, Garcia-Pras E, Abraldes JG, Garcia-Pagan JC, Fernandez M, Bosch J: Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats. Am J Physiol Gastrointest Liver Physiol 2012, 302:G1191-8.
160. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JC, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shaun M, Moscovici M, Voliotis D, Bruix J: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-90.
161. Hennenberg M, Trebicka J, Stark C, Kohistani AZ, Heller J, Sauerbruch T: Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis. Br J Pharmacol 2009, 157:258-70.
162. Pinter M, Sieghart W, Reiberger T, Rohr-Udilova N, Ferlitsch A, Peck- Radosavljevic M: The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma-a pilot study. Aliment Pharmacol Ther 2012, 35:83-91.
163. Yovchev MI, Xue Y, Shafritz DA, Locker J, Oertel M: Repopulation of the fibrotic/cirrhotic rat liver by transplanted hepatic stem/progenitor cells and mature hepatocytes. Hepatology 2014, 59:284-95.
164. Ricci E, Vanosi G, Lindenmair A, Hennerbichler S, Peterbauer- Scherb A, Wolbank S, Cargnoni A, Signoroni PB, Campagnol M, Gabriel C, Redl H, Parolini O: Anti-fibrotic effects of fresh and cryopreserved human amniotic membrane in a rat liver fibrosis model. Cell Tissue Bank 2013, 14:475-88.
165. Zheng L, Chu J, Shi Y, Zhou X, Tan L, Li Q, Cui L, Han Z, Han Y1, Fan D: Bone marrow-derived stem cells ameliorate hepatic fibrosis by down-regulating interleukin-17. Cell Biosci 2013, 3:46.
166. Desmet VJ: Comments on cirrhosis reversal. Dig Liver Dis 2005, 37:909-16.
167. Lee YA, Friedman SL: Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? Antiviral Res 2014, 107:23-30.
168. Muting D, Kalk JF, Fischer R, Wiewel D: Spontaneous regression of oesophageal varices after long-term conservative treatment. Retrospective study in 20 patients with alcoholic liver cirrhosis, posthepatitic cirrhosis and haemochromatosis with cirrhosis. J Hepatol 1990, 10:158-62.
169. Reynolds TB, Geller HM, Kuzma OT, Redeker AG: Spontaneous decrease in portal pressure with clinical improvement in cirrhosis. N Engl J Med 1960, 263:734-9.
170. Hammel P, Couvelard A, O'Toole D, Ratouis A, Sauvanet A, Fléjou JF, Degott C, Belghiti J, Bernades P, Valla D, Ruszniewski P, Lévy P: Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med 2001, 344:418-23.
171. Dixon JB, Bhathal PS, Hughes NR, O 'Brien PE: Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 2004, 39:1647-54.
172. Falize L, Guillygomarc'h A, Perrin M, Laine F, Guyader D, Brissot P, Turlin B, Deugnier Y: Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology 2006, 44:472-7.
173. Czaja AJ, Carpenter HA: Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004, 40:646-52.
174. Roberts S, Gordon A, McLean C, Pedersen J, Bowden S, Thomson K, Angus P: Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis. Clin Gastroenterol Hepatol 2007, 5:932-7.
175. Manne V, Akhtar E, Saab S: Cirrhosis Regression in Patients With Viral Hepatitis B and C: A Systematic Review. J Clin Gastroenterol 2014, 48:e76-84.
176. Akhtar E, Manne V, Saab S: Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-analysis. Liver Int 2014, [Epub ahead of print].
177. Casado JL, Quereda C, Moreno A, Perez-Elias MJ, Marti-Belda P, Moreno S: Regression of liver fibrosis is progressive after sustained virological response to HCV therapy in patients with hepatitis C and HIV coinfection. J Viral Hepat 2013, 20:829-37.
178. Calvaruso V, Craxi A: Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible? Liver Int 2014, 34(Suppl 1):85-90.
179. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, Albrech: Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002, 122:1303-13.
180. D'Ambrosio R, Aghemo A, Rumi MG, Ronchi G, Donato MF, Paradis V, Colombo M, Bedossa P: A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 2012, 56:532-43.
181. Issa R, Zhou X, Constandinou CM, Fallowfield J, Millward-Sadler H, Gaca MD, Sands E, Suliman I, Trim N, Knorr A, Arthur MJ, Benyon RC, Iredale JP: Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 2004, 126:1795-808.
182. Issa R, Zhou X, Trim N, Millward-Sadler H, Krane S, Benyon C, Iredale J: Mutation in collagen-1 that confers resistance to the action of collagenase results in failure of recovery from CCl4-induced liver fibrosis, persistence of activated hepatic stellate cells, and diminished hepatocyte regeneration. FASEB J 2003, 17:47-9.
183. Wanless IR, Nakashima E, Sherman M: Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med 2000, 124:1599-607.